Table 1.
Patient characteristics
| Characteristic | Treatment arm | P | |
|---|---|---|---|
| KLH-only arm | Id-KLH arm | ||
| Sex | .82 | ||
| Female | 8 (40) | 7 (43.8) | |
| Male | 12 (60) | 9 (56.3) | |
| Race | .85 | ||
| Black | 2 (10) | 3 (18.8) | |
| M | 2 (10) | 1 (6.3) | |
| White | 16 (80) | 12 (75) | |
| Cytogenetic risk | .68 | ||
| High | 3 (15) | 4 (25) | |
| Standard | 17 (85) | 12 (75) | |
| International Staging System | .69 | ||
| I | 13 (72.2) | 7 (63.6) | |
| II, III | 5 (27.8) | 4 (36.4) | |
| LDH | 1.00 | ||
| >Normal | 2 (11.8) | 1 (8.3) | |
| Normal | 15 (88.2) | 11 (91.7) | |
| Response before transplantation | .35 | ||
| NCR | 0 (0) | 1 (6.3) | |
| VGPR | 1 (5) | 3 (18.8) | |
| PR | 14 (70) | 8 (50) | |
| SD | 2 (10) | 3 (18.8) | |
| PD | 3 (15) | 1 (6.3) | |
| Induction | .48 | ||
| VRD | 15 (75) | 10 (62) | |
| VCD | 4 (20) | 5 (31) | |
| Maintenance | 19 (95) | 16 (100) | .29 |
| Lenalidomide | 10 | 12 | |
| Lenalidomide based | 8 | 4 | |
| Pomalidomide | 1 | 0 | |
Data are presented as n (%).
LDH, lactate dehydrogenase; NCR, near CR; PD, progressive disease; SD, stable disease; VCD, bortezomib, cyclophosphamide, and dexamethasone; VRD, bortezomib, lenalidomide, and dexamethasone.